Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04410445 · ClinicalTrials.gov registry record · Phase 3
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
A Phase 3 study, sponsored by Nektar Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 765
- Enrollment target
NCT04410445 is a Phase 3 study that was terminated before completion, run by Nektar Therapeutics. The registered enrollment target is 765 participants.
The verdict
NCT04410445, a Phase 3 study, was terminated before completion, sponsored by Nektar Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 765 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare the efficacy of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIA/B/C/D, or Stage IV cutaneous melanoma who are at high risk for recurrence.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Bempegaldesleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 765 participants |
| Start Date | 2020-07-27 |
| Est. Completion | 2022-09-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04410445
The ClinicalTrials.gov registry entry for NCT04410445 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 765 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT04410445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04410445 about?
NCT04410445 is a clinical study titled "Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence". The main purpose of this study is to compare the efficacy of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIA/B/C/D, or Stage IV cutaneous melanoma who are at high risk for recurrence.
What is the current status of trial NCT04410445?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 765 participants. The study started on 2020-07-27. Estimated completion is 2022-09-22.
What interventions are being tested in trial NCT04410445?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Bempegaldesleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT04410445?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.